Advanced search
Log in
Press Room
Releases
Multimedia
About
SAP Patent Family Entirely Approved
5/9/2012 5:14 AM EST
ArcticZymes AS finalizes its protection of the SAP patent family
TROMSØ, NORWAY, May 9, 2012 - ArcticZymes AS, a subsidiary of Biotec Pharmacon ASA (TICKER: BIOTEC) has received a Notice of Allowance for the Norwegian patent application of the SAP-patent family.
The allowed patent covers the product and its use as well as the method of producing SAP, ArcticZymes' top-selling enzyme Shrimp Alkaline Phosphatase (SAP). With the approval of this new patent in Norway, ArcticZymes has now a comprehensive patent protection for SAP. There are no further patent applications pending in this patent family, all have been approved. Aside the recently granted Norwegian patent, the SAP-technology is now protected in 17 other countries including major markets like the USA, Japan, UK, Germany, France and Italy.
Adding this patent application to the already large and strong portfolio of existing patent families protecting its main phosphatase, glycosylase and nuclease products, ArcticZymes has...
Biotec Pharmacon presenting Woulgan® Biogel at BIO-Europe Spring 2012
3/21/2012 5:01 AM EST
CEO Svein W. F. Lien and Director IP & BD Alexander Bjørnå are presenting Biotec Pharmacon at BIO-Europe Spring 2012 in Amsterdam 20 and 21 March.
The presentation introduces...
ArcticZymes AS Files New Enzyme Patent Application
2/20/2012 2:00 AM EST
ArcticZymes AS strengthens its proprietary patent portfolio by protecting a new endonuclease product and its use
TROMSØ, NORWAY, February 20, 2012 – ArcticZymes AS, a...
Biotec Pharmacon ASA Solidifies Efforts In Cancer Adjuvant Therapy
2/16/2012 2:43 AM EST
Biotec Pharmacon ASA strengthens its proprietary patent coverage for the combination of monoclonal antibodies and yeast beta glucan for treatment of different types of cancer
ArcticZymes establishes US subsidiary
1/11/2012 7:14 AM EST
Providing cold adapted and heat-labile unique Enzymes for the Research and Molecular Diagnostics Market in North America
Tromso, Norway, January 11, 2012 – ArcticZymes AS...
Biotec Pharmacon ASA Issued New Patent for Cancer Adjuvant Therapy
10/26/2011 8:43 AM EST
Latest Patent Covers The Combination of Monoclonal Antibodies and Yeast Beta Glucan For Treatment of Different Types Of Cancer
TROMSØ, NORWAY, October 26, 2011 – Biotec...
SEE ALL NEWS
Biotec Pharmacon ASA
RSS
Subscribe by Email
View more
Tweet
Media
more